Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from its Cloudbreak® Platform
CBO-212 is a first-in-class inhibitor of CD73 cancer immunotherapy targetSAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc....